GoodRx Holdings (GDRX) Net Income towards Common Stockholders (2019 - 2026)

GoodRx Holdings has disclosed Net Income towards Common Stockholders across 8 years of filings, most recently posting $1.2 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $1.2 million, down 89.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.6 million (down 27.75% YoY), and the FY2025 annual result was $30.4 million, up 85.72% from the prior year.
• Net Income towards Common Stockholders came in at $1.2 million for Q1 2026 at GoodRx Holdings, down from $5.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $58.8 million in Q2 2023 to a low of -$41.7 million in Q3 2022.
• The 5-year median for Net Income towards Common Stockholders is $1.2 million (2026), against an average of $370705.9.
• Peak annual rise in Net Income towards Common Stockholders reached 4254.49% in 2023, while the deepest fall reached 1211.82% in 2023.
• GoodRx Holdings' Net Income towards Common Stockholders stood at -$2.0 million in 2022, then slumped by 1211.82% to -$25.9 million in 2023, then soared by 126.05% to $6.7 million in 2024, then declined by 19.51% to $5.4 million in 2025, then tumbled by 78.45% to $1.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $1.2 million (Q1 2026), $5.4 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.